Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo

BACKGROUND: The therapeutic armamentarium of bladder cancer has been recently enriched with the introduction of new therapies including immune checkpoint inhibitors, receptor tyrosine kinase inhibitors and antibody drug conjugates, however treatment responses and duration of responses are still less...

Descripción completa

Detalles Bibliográficos
Autores principales: Bunch, Brittany L, Morse, Jennifer, Asby, Sarah, Blauvelt, Jamie, Aydin, Ahmet M, Innamarato, Patrick, Hajiran, Ali, Beatty, Matthew, Poch, Michael, Pilon-Thomas, Shari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733200/
https://www.ncbi.nlm.nih.gov/pubmed/33303579
http://dx.doi.org/10.1136/jitc-2020-001673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733200/
https://www.ncbi.nlm.nih.gov/pubmed/33303579
http://dx.doi.org/10.1136/jitc-2020-001673

Ejemplares similares